Fig. 7
From: The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer
Assessment of the expression level of CACNA1H (Cav3.2) in SKBR3 derived trastuzumab-resistant cell lines, different breast cancer cell lines and non-malignant breast cell lines. Cav3.2 was not detected (ND) in non-malignant breast cell lines and the basal breast cancer cell lines MDA-MB-231 and MDA-MB-468. The luminal cell lines MCF-7 and T47D showed the highest expression of Cav3.2. Statistical analysis was performed within each subtype and trastuzumab-resistant cell lines were compared to the SV1 trastuzumab sensitive SKBR3 cell line. For all amplified targets (n = 3 ±SD), statistical analysis was performed using one-way ANOVA with Bonferroni post-test (*p ≤ 0.05, **p ≤ 0.01)